Jump to main content
Jump to site search


Artificial macrocycles as IL-17A/IL-17RA antagonists

Author affiliations

Abstract

Interleukin 17(A) is a pro-inflammatory cytokine involved in several auto-immune and inflammatory diseases. Current antagonists against IL-17(A) or its receptor (IL-17RA) that show efficacy in clinical trials are monoclonal antibodies (mAbs). However, recently designed artificial macrocycles are potent IL-17A/IL-17RA antagonists. Based on co-crystal structures, a better understanding of the biological activity and SAR of the macrocycles has been gained, demonstrating that they can compete with mAbs for difficult targets such as PPIs.

Graphical abstract: Artificial macrocycles as IL-17A/IL-17RA antagonists

Back to tab navigation

Publication details

The article was received on 12 Sep 2017, accepted on 24 Oct 2017 and first published on 25 Oct 2017


Article type: Review Article
DOI: 10.1039/C7MD00464H
Citation: Med. Chem. Commun., 2017, Advance Article
  •   Request permissions

    Artificial macrocycles as IL-17A/IL-17RA antagonists

    W. Wang, M. R. Groves and A. Dömling, Med. Chem. Commun., 2017, Advance Article , DOI: 10.1039/C7MD00464H

Search articles by author

Spotlight

Advertisements